A committee established by the DOTS-Plus Working Group to review applications from potential DOTS-Plus pilot projects to determine whether projects meet criteria for receiving funding, to ensure programmatic success, and to limit the possibility of creating drug resistance to second-line TB drugs - which are the last line of defense against TB.